SCHEDULE 13G

CUSIP No.

14147L108

1

Names of Reporting Persons

Pfizer Inc. 13-5315170

2

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,411,575.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,411,575.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,411,575.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

11

Percent of class represented by amount in row (9)

3.6 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: (See row 11) Based on 66,524,182 shares of Common Stock outstanding as reported in the Issuer's prospectus supplement, filed with the U.S. Securities and Exchange Commission (the "Commission") on December 10, 2024, to the Issuer's effective shelf registration statement on Form S-3, which was originally filed with the Commission on April 25, 2022 (File No. 333-264148).

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Cardiff Oncology, Inc.

(b)

Address of issuer's principal executive offices:

11055 Flintkote Avenue, San Diego, CA, 92121

Item 2.

(a)

Name of person filing:

Pfizer Inc.

(b)

Address or principal business office or, if none, residence:

66 Hudson Boulevard East, New York, NY 10001

(c)

Citizenship:

Delaware, U.S.A.

(d)

Title of class of securities:

Common Stock, $0.0001 par value per share

(e)

CUSIP No.:

14147L108

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

See rows 5 through 11 of the cover page.

(b)

Percent of class:

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

(ii) Shared power to vote or to direct the vote:

(iii) Sole power to dispose or to direct the disposition of:

(iv) Shared power to dispose or to direct the disposition of:

Item 5.

Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Pfizer Inc. 13-5315170

Signature:	/s/ Madelyn D. Purcell
Name/Title:	Madelyn D. Purcell/Assistant Secretary
Date:	02/12/2025